Ziopharm Oncology (ZIOP) soars 10.3% after saying its palifosfamide (ZIO-201) treatment...

Ziopharm Oncology (ZIOP) soars 10.3% after saying its palifosfamide (ZIO-201) treatment performed well in patients with metastatic soft tissue sarcoma in a Phase III trial, with the drug reaching its target number for progression-free survival. The company will release full results in March. (PR)

Comments (2)
  • Hope4Future
    , contributor
    Comments (291) | Send Message
    Please point me to the press release where it says Palifosfamide "performed well". The announcement I saw did not say this. It simply said they reached the target PFS for unblinding. If I am right and you misquoted, you need to retract this before the market opens.
    12 Feb 2013, 09:17 AM Reply Like
  • Same as Poker
    , contributor
    Comments (17) | Send Message
    should redact!
    12 Feb 2013, 09:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs